Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Assertio Holdings Inc's Business Segments
Assertio Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
10
Largest Segment
Total product sales net
Total Revenue
$ 10
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Total product sales net89.6%
- Product sales net89.6%
- INDOCIN products34.7%
- Sympazan26%
- SPRIX13.8%
- Other products10.2%
- Other revenue6%
- ROLVEDON5%
- Royalty revenue4.4%
- CAMBIA Canada4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total product sales net | $ 9 | 89.6% |
| Product sales net | $ 9 | 89.6% |
| INDOCIN products | $ 3 | 34.7% |
7 more segments available
Sign in to unlock the full Assertio Holdings Inc dataset.
Revenue by Product & Service Category - FY
- Product89.6%
- INDOCIN products34.7%
- Sympazan26%
- Sprix Nasal Spray13.8%
- Product, Other10.2%
- Product and Service, Other6%
- ROLVEDON5%
- Royalty4.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 9 | 89.6% |
| INDOCIN products | $ 3 | 34.7% |
| Sympazan | $ 3 | 26% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
5 more categories available
Sign in to unlock the full Assertio Holdings Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Total product sales net89.6%
- Product sales net89.6%
- INDOCIN products34.7%
- Sympazan26%
- SPRIX13.8%
- Other products10.2%
- Other revenue6%
- ROLVEDON5%
- Royalty revenue4.4%
- CAMBIA Canada4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Total product sales net | $ 9 | 89.6% |
| Product sales net | $ 9 | 89.6% |
| INDOCIN products | $ 3 | 34.7% |
7 more segments available
Sign in to unlock the full Assertio Holdings Inc dataset.
Description of Assertio Holdings Inc
Assertio Holdings Inc. remains committed to delivering high-quality products and to meeting the needs of its customers.
In summary, Assertio Holdings Inc. is a specialty pharmaceutical company that develops and markets drugs for the treatment of various diseases. The company has a strong focus on quality control and regulatory adherence, and is committed to bringing new and innovative products to market. Despite facing some challenges in recent years, the company remains a leader in the pharmaceutical industry and is poised for future growth and success.
In summary, Assertio Holdings Inc. is a specialty pharmaceutical company that develops and markets drugs for the treatment of various diseases. The company has a strong focus on quality control and regulatory adherence, and is committed to bringing new and innovative products to market. Despite facing some challenges in recent years, the company remains a leader in the pharmaceutical industry and is poised for future growth and success.
Assertio Holdings Inc. operates through two distinct segments: Specialty Pharmaceuticals and Contract Manufacturing, each contributing uniquely to the company’s overall operations and strategic objectives. Below is an extensive overview of these segments, the products offered, and the services provided.
Segments
Specialty Pharmaceuticals
The Specialty Pharmaceuticals segment is at the core of Assertios mission, focusing on the commercialization of branded prescription products primarily within the fields of neurology, orphan diseases, and specialized therapeutic areas. This segment manages a diverse portfolio of products, which are designed to cater to the unique needs of patients dealing with complex health conditions. Assertio is dedicated to driving value in this segment by continually exploring innovative treatments and building a robust pipeline of products aimed at underserved patient populations.
Key Products in the Specialty Pharmaceuticals Segment:
- Gralise: An antiepileptic agent, Gralise is utilized for treating postherpetic neuralgia (PHN), which is characterized by nerve pain following shingles. Gralise allows patients to manage chronic pain more effectively and has been positively received due to its targeted therapeutic approach.
- Cambia: This non-steroidal anti-inflammatory drug (NSAID) is specifically indicated for the treatment of acute migraine attacks, with or without aura, in adult patients. Cambia offers rapid relief for patients experiencing the debilitating effects of migraines.
- Lazanda: A fentanyl nasal spray designed for managing breakthrough pain in adults with cancer who already exhibit a level of tolerance to opioid therapies. Lazanda provides an effective means of addressing sudden, intense pain episodes, enhancing quality of life for patients in critical care situations.
- Zipsor: Another NSAID in Assertio’s portfolio, Zipsor is utilized for the relief of mild to moderate pain. It serves as an accessible option for pain management across various settings.
Contract Manufacturing
The Contract Manufacturing segment of Assertio Holdings specializes in the manufacture and distribution of externally developed pharmaceutical products, with a distinct emphasis on controlled substances. This segment leverages Assertios expertise in advanced manufacturing techniques and quality assurance processes to ensure that the products meet stringent regulatory standards.
Key Functions in the Contract Manufacturing Segment:
- Manufacturing: Assertio’s state-of-the-art manufacturing facilities enable the production of both controlled substances and generic products. The company offers comprehensive active pharmaceutical ingredient (API) manufacturing services, ensuring quality and consistency in the production process.
- Analytical Services: Assertio provides a range of analytical services to support its manufacturing operations. These include method development and validation, stability studies, impurity identification, and more, all crucial for ensuring that products meet safety and efficacy standards.
- Development Activities: The development arm of the Contract Manufacturing segment includes formulation development, pre-formulation studies, and process development. Assertio focuses on optimizing manufacturing processes, conducting scale-up operations, and facilitating tech transfers, which are essential for bringing new products to market efficiently and successfully.
Summary
Assertio Holdings Inc. is well-positioned in both the Specialty Pharmaceuticals and Contract Manufacturing segments, combining therapeutic development and advanced manufacturing capabilities. With a commitment to innovation and quality, Assertio aims to address critical healthcare needs while supporting the pharmaceutical industrys demand for high-quality, compliant manufacturing solutions. The company’s diverse product offerings and service capabilities underline its strategic focus on enhancing patient care and operational excellence.
Segments
Specialty Pharmaceuticals
The Specialty Pharmaceuticals segment is at the core of Assertios mission, focusing on the commercialization of branded prescription products primarily within the fields of neurology, orphan diseases, and specialized therapeutic areas. This segment manages a diverse portfolio of products, which are designed to cater to the unique needs of patients dealing with complex health conditions. Assertio is dedicated to driving value in this segment by continually exploring innovative treatments and building a robust pipeline of products aimed at underserved patient populations.
Key Products in the Specialty Pharmaceuticals Segment:
- Gralise: An antiepileptic agent, Gralise is utilized for treating postherpetic neuralgia (PHN), which is characterized by nerve pain following shingles. Gralise allows patients to manage chronic pain more effectively and has been positively received due to its targeted therapeutic approach.
- Cambia: This non-steroidal anti-inflammatory drug (NSAID) is specifically indicated for the treatment of acute migraine attacks, with or without aura, in adult patients. Cambia offers rapid relief for patients experiencing the debilitating effects of migraines.
- Lazanda: A fentanyl nasal spray designed for managing breakthrough pain in adults with cancer who already exhibit a level of tolerance to opioid therapies. Lazanda provides an effective means of addressing sudden, intense pain episodes, enhancing quality of life for patients in critical care situations.
- Zipsor: Another NSAID in Assertio’s portfolio, Zipsor is utilized for the relief of mild to moderate pain. It serves as an accessible option for pain management across various settings.
Contract Manufacturing
The Contract Manufacturing segment of Assertio Holdings specializes in the manufacture and distribution of externally developed pharmaceutical products, with a distinct emphasis on controlled substances. This segment leverages Assertios expertise in advanced manufacturing techniques and quality assurance processes to ensure that the products meet stringent regulatory standards.
Key Functions in the Contract Manufacturing Segment:
- Manufacturing: Assertio’s state-of-the-art manufacturing facilities enable the production of both controlled substances and generic products. The company offers comprehensive active pharmaceutical ingredient (API) manufacturing services, ensuring quality and consistency in the production process.
- Analytical Services: Assertio provides a range of analytical services to support its manufacturing operations. These include method development and validation, stability studies, impurity identification, and more, all crucial for ensuring that products meet safety and efficacy standards.
- Development Activities: The development arm of the Contract Manufacturing segment includes formulation development, pre-formulation studies, and process development. Assertio focuses on optimizing manufacturing processes, conducting scale-up operations, and facilitating tech transfers, which are essential for bringing new products to market efficiently and successfully.
Summary
Assertio Holdings Inc. is well-positioned in both the Specialty Pharmaceuticals and Contract Manufacturing segments, combining therapeutic development and advanced manufacturing capabilities. With a commitment to innovation and quality, Assertio aims to address critical healthcare needs while supporting the pharmaceutical industrys demand for high-quality, compliant manufacturing solutions. The company’s diverse product offerings and service capabilities underline its strategic focus on enhancing patient care and operational excellence.